Efficacy and Safety of Maintenance Immune Checkpoint Inhibitors With or Without Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer

BMC Cancer

ICIs with or without pemetrexed can be used as maintenance therapy after first-line ICIs plus 4–6 cycles of pemetrexed/platinum in patients with advanced NS-NSCLC based on PD-L1 expression.